In a phase 2 trial, more than half of patients who received neoadjuvant chemotherapy for high-risk upper tract urothelial carcinoma had a pathologic response that was associated with improved survival.
In a study, nearly 1 in 10 cancer patients on systemic therapy experienced an episode of acute kidney injury.
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment.
Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.
One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.
Among patients with short-term peripherally inserted central catheter, about 1 in 10 has a complication
Better reimbursement at hospital outpatient depts, even though drug-level costs lower in doctor’s office
Certain chemotherapies might shorten telomeres and alter microRNA.
Decrease in estimated out-of-pocket spending at the 25th, 50th, 75th percentiles; increase at 90th, 95th
Radical cystectomy is associated with better survival, but findings suggest BPT may produce acceptable oncologic outcomes in appropriately selected patients.
